$FMHS
FARMHOUSE, INC. /NV Stock $fmhs

$fmhs Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000109690623001126 Filed on May 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$1.069K	$2.640K	$0.00
YoY Change		1220.0%	-100.0%
Cost Of Revenue	$535.00	$1.320K	$0.00
YoY Change		-83.5%	-100.0%
Gross Profit	$534.00	$1.320K	$0.00
YoY Change		-116.92%	-100.0%
Gross Profit Margin	49.95%	50.0%
Selling, General & Admin	$159.3K	$141.1K	$218.3K
YoY Change	-27.02%	-58.47%	64.81%
% of Gross Profit	29837.08%	10690.15%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$90.00
YoY Change	-100.0%	-100.0%	-70.0%
% of Gross Profit	0.0%	0.0%
Operating Expenses	$159.3K	$141.1K	$218.4K
YoY Change	-27.05%	-58.5%	64.5%
Operating Profit	-$158.8K	-$139.8K	-$218.4K
YoY Change	-27.29%	-59.81%	68.76%
Interest Expense	$12.52K	$212.6K	-$15.81K
YoY Change	-179.19%	-2331.06%	99.87%
% of Operating Profit
Other Income/Expense, Net	-$12.52K	$0.00	-$15.81K
YoY Change	-20.8%
Pretax Income	-$171.3K	$72.58K	-$234.2K
YoY Change	-26.86%	-120.31%	70.55%
Income Tax
% Of Pretax Income
Net Earnings	-$171.3K	$72.58K	-$234.2K
YoY Change	-26.86%	-120.31%	70.56%
Net Earnings / Revenue	-16025.72%	2749.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.01	$0.00	-$14.87K
COMMON SHARES
Basic Shares Outstanding		17.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.680K	$62.06K	$830.00
YoY Change	945.78%	1541.8%
Cash & Equivalents	$8.678K	$62.06K	$830.00
Short-Term Investments
Other Short-Term Assets	$7.980K	$3.810K	$7.620K
YoY Change	4.72%	1.6%
Inventory
Prepaid Expenses	$7.980K	$3.810K
Receivables	$1.069K	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$17.73K	$65.87K	$8.450K
YoY Change	109.79%	774.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$250.00
YoY Change	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$17.73K	$65.87K	$8.450K
Total Long-Term Assets	$0.00	$0.00	$250.00
Total Assets	$17.73K	$65.87K	$8.700K
YoY Change	103.76%	736.59%	787.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.80K	$11.18K	$9.050K
YoY Change	162.93%	17.69%	-70.43%
Accrued Expenses	$168.1K	$156.1K	$1.389M
YoY Change	-87.9%	54.82%	38.97%
Deferred Revenue
YoY Change
Short-Term Debt	$95.00K	$95.00K	$127.7K
YoY Change	-25.58%	-20.85%	183.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.715M	$1.650M	$1.684M
YoY Change	1.81%	4.48%	36.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.715M	$1.650M	$1.684M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.715M	$1.650M	$1.684M
YoY Change	1.81%	4.48%	36.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.916M	-$5.745M
YoY Change		8.35%
Common Stock	$1.708K	$1.708K
YoY Change		8.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.697M	-$1.584M	-$1.675M
YoY Change
Total Liabilities & Shareholders Equity	$17.73K	$65.87K	$8.700K
YoY Change	103.76%	736.59%	787.76%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$171.3K	$72.58K	-$234.2K
YoY Change	-26.86%	-120.31%	70.56%
Depreciation, Depletion And Amortization	$0.00	$0.00	$90.00
YoY Change	-100.0%	-100.0%	-70.0%
Cash From Operating Activities	-$35.13K	-$10.15K	-$45.66K
YoY Change	-23.07%	-81.94%	455.47%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$225.0K	$0.00
YoY Change
Cash From Investing Activities	$0.00	$225.0K	$0.00
YoY Change		-90100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$18.26K	-268.9K	42.71K
YoY Change	-142.75%	-1864.44%	890.95%
NET CHANGE
Cash From Operating Activities	-$35.13K	-10.15K	-45.66K
Cash From Investing Activities	$0.00	225.0K	0.000
Cash From Financing Activities	-$18.26K	-268.9K	42.71K
Net Change In Cash	-$53.39K	-54.05K	-2.950K
YoY Change	1709.66%	31.16%	-24.55%
FREE CASH FLOW
Cash From Operating Activities	-$35.13K	-$10.15K	-$45.66K
Capital Expenditures		$0.00
Free Cash Flow		-$10.15K
YoY Change		-81.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity File Number EntityFileNumber	333-238326
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3321759
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	548 Market Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 90355
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94104
CY2023Q1	dei	City Area Code CityAreaCode	888
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	420-6856
CY2023Q1	dei	Phone Fax Number Description PhoneFaxNumberDescription	Registrant’s telephone number
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17075950	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8678	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62063	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1069	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7980	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3810	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	17727	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65873	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q1	us-gaap	Assets Assets	17727	usd
CY2022Q4	us-gaap	Assets Assets	65873	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	23795	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11181	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	357921	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	535	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	534	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	348137	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	991644	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	945608	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	168050	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	156050	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	51667	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	48931	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	50000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	50000	usd
CY2023Q1	fil	Due To Related Parties1 DueToRelatedParties1	26622	usd
CY2022Q4	fil	Due To Related Parties1 DueToRelatedParties1	44882	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1714699	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1649789	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17075950	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17075950	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17075950	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17075950	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1708	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1708	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4217334	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4159075	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5916014	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5744699	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1696972	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1583916	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17727	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65873	usd
CY2023Q1	us-gaap	Revenues Revenues	1069	usd
CY2022Q1	us-gaap	Revenues Revenues	0	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	84679	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92586	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	74650	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	125729	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	94	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	159329	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	218409	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-158795	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-218409	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	12520	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	15808	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12520	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15808	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-171315	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-234217	usd
CY2023Q1	fil	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.01
CY2022Q1	fil	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.01
CY2023Q1	fil	Basic And Diluted Weighted Average Number Of Shares Outstanding BasicAndDilutedWeightedAverageNumberOfSharesOutstanding	17075950	shares
CY2022Q1	fil	Basic And Diluted Weighted Average Number Of Shares Outstanding BasicAndDilutedWeightedAverageNumberOfSharesOutstanding	15753092	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1583916	usd
CY2023Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	58259	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-171315	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1696972	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1571243	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35105	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	69412	usd
CY2022Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	25500	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-234217	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1675443	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-171315	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-234217	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	69412	usd
CY2023Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	58259	usd
CY2022Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	25500	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1069	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4170	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3870	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12614	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-455	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9784	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	28480	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	46036	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	46036	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	20254	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2736	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	3106	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35125	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45660	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35105	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7620	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	18260	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	16	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18260	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42709	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-53385	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2951	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62063	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3780	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8678	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	829	usd
CY2023Q1	us-gaap	Interest Paid InterestPaid	0	usd
CY2022Q1	us-gaap	Interest Paid InterestPaid	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Organization</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The Company was incorporated in June 2013 as Somerset Transition Corporation under the Oklahoma General Corporation Act. The Company was formed to complete a reorganization under Section 1088(g) of the Oklahoma Act, whereby the Company became successor to Transnational Financial Network, Inc., which was originally incorporated in California in 1985. In September 2013, the Company was redomesticated in Maryland and changed its name to Somerset Property, Inc. In July 2017, the Company was redomesticated in Nevada and changed its name to Revival, Inc. In June 2019, the Company changed its name to Farmhouse, Inc. to reflect its new business endeavors. </p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">In August 2019, the Company acquired Farmhouse, Inc., a Washington corporation (“Farmhouse Washington”) as its wholly owned subsidiary (the “Acquisition”). Farmhouse Washington was formed in January 2014 and has developed a social network platform, “The WeedClub® Platform”. At the closing of the Acquisition, all of the issued and outstanding shares of common stock of Farmhouse Washington were exchanged for shares of common stock of the Company on a one-for-one basis. The financial statements of the Company are the continuation of Farmhouse Washington with the adjustment to reflect the capital structure of the Company. </p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">Prior to the Acquisition, in August 2017, Farmhouse Washington formed Farmhouse DTLA, Inc. (“DTLA”) in California as a wholly owned subsidiary. In April 2021, DTLA was awarded a 49% equity interest in a Los Angeles based multi-licensed cannabis retail dispensary, grow, manufacturer and distributor called Los Angeles Farmers, Inc. (“LAFI”). Although ownership percentages over 20% would typically be accounted for using the equity method, the Company is accounting for this investment as an investment in equity securities due to the Company not having significant influence over LAFI. The cost of this investment was expensed during the fiscal year ended December 31, 2017 and, due to uncertainties surrounding the value of LAFI and determining any award of back profits and interest, as well as the pending litigation, no value has been reflected in our unaudited interim condensed consolidated financial statements as of March 31, 2023. See Note 9.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Current Operations</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The Company is a technology company with multiple cannabis related divisions and IP, including the WeedClub® Platform, the @420 Twitter handle and a Web3 division. The WeedClub® Platform is a cannabis social network platform that enables industry professionals to connect, discover products and services and scale their businesses. Within the WeedClub® Platform, members utilize an increasing set of technology-based tools for discovering professional connections and information. The Company’s @420 Twitter handle serves as a public platform to engage with cannabis enthusiasts. The Company’s Web3 division, launched in December 2021, facilitates licensing opportunities between established cannabis brands and influential digital collectible holders to launch digital collectible branded products and accessories<span style="background-color:#FFFFFF">.</span></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Going Concern and Management’s Plans</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The accompanying unaudited interim condensed consolidated financial statements have been presented on the basis that the Company is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2023, </p> <p style="font:11pt Times New Roman;margin:0">the Company had a net loss from operations of $158,795 and as of March 31, 2023, the Company had stockholders’ deficit of $1,696,972. In view of these matters, the recoverability of any asset amounts shown in the accompanying unaudited interim condensed consolidated financial statements is dependent upon the Company’s ability to expand operations and achieve profitability from its business. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These unaudited interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The Company has financed its activities principally from the sale of its common stock and loans from Company officers. The Company intends to finance its future working capital needs from these sources until such time that funds provided by operations are sufficient to fund working capital requirements. Management believes that the current cash on hand, loans from Company officers and funds raised from the sale of its common stock allow the Company sufficient capital for operations and to continue as a going concern.</p>
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-158795	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1696972	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Financial Statement Reclassification</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">Certain amounts from the prior year’s financial statements have been reclassified in these unaudited interim condensed consolidated financial statements to conform to the current year’s classifications.</p>
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Use of Estimates</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;color:#000000">Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the carrying value of property and equipment, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. The Company evaluates its estimates based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.</p>
CY2023Q1	us-gaap	Revenues Revenues	1069	usd
CY2022Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	535	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	534	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q1	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	7312	usd
CY2022Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	7312	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7312	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7312	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q1	fil	Due To Related Parties1 DueToRelatedParties1	26622	usd
CY2022Q4	fil	Due To Related Parties1 DueToRelatedParties1	44882	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	18260	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	16	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17075950	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35105	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	69412	usd
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15836350	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	752000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.251
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	192000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.303
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	560000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.232
CY2023Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	58259	usd
CY2022Q1	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	25500	usd
CY2023Q1	fil	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	130165	usd
CY2022Q4	fil	Due To Related Parties1 DueToRelatedParties1	44882	usd

Files In Submission

Name	View Source	Status
0001096906-23-001126-index-headers.html	Edgar Link	pending
0001096906-23-001126-index.html	Edgar Link	pending
0001096906-23-001126.txt	Edgar Link	pending
0001096906-23-001126-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fmhs-20230331.htm	Edgar Link	pending
fmhs-20230331.xsd	Edgar Link	pending
fmhs_ex31z1.htm	Edgar Link	pending
fmhs_ex31z2.htm	Edgar Link	pending
fmhs_ex32z1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
fmhs-20230331_cal.xml	Edgar Link	unprocessable
fmhs-20230331_def.xml	Edgar Link	unprocessable
fmhs-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
fmhs-20230331_lab.xml	Edgar Link	unprocessable
fmhs-20230331_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FMHS
FARMHOUSE, INC. /NV Stock $fmhs

2023 Q1 Form 10-Q Financial Statement

#000109690623001126 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FMHS FARMHOUSE, INC. /NV Stock $fmhs

2023 Q1 Form 10-Q Financial Statement

#000109690623001126 Filed on May 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FMHS
FARMHOUSE, INC. /NV Stock $fmhs